Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Synairgen engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease and severe viral infections, as well as COVID-19. The company was founded by Donna E. Davies, Ratko Djukanovic, and Stephen T. Holgate in June 2003 and is headquartered in Southampton.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as advisor to Synairgen plc in this transaction.

Service

Funding, debt advisory & ECM

Parties

“It was particularly pleasing to see the level of support received for this financing, reinforcing confidence in SNG001, our wholly-owned drug and potential breakthrough treatment for COVID-19 patients. Oaklins’ team has always been supportive and built a good register of institutions in March which was broadened further in this funding. It was a very successful fundraising and the level of demand was such that we were comfortably able to increase the size of the funding. Having demonstrated the great promise of SNG001 in hospitalized COVID-19 patients earlier this year, we now have the resources to be able to rapidly progress this potential breakthrough treatment in such a critical area of unmet need.”

Richard Marsden

CEO, Synairgen plc

Talk to the deal team

Geoff Nash

Director

London, United Kingdom
Oaklins Cavendish

View profile Get in touch

Related deals

Tekova Oyj has completed a technical listing on the Nasdaq First North Growth Market Finland

Construction & Engineering Services

Tekova Oyj has completed a technical listing on the Nasdaq First North Growth Market Finland

Tekova Oyj has successfully completed a technical listing (IPO) on the Nasdaq First North Growth Market Finland. This transaction marks a significant milestone in the company’s growth strategy, enhancing its visibility and access to capital markets.

Learn more

Bayer AG has entered into a takeover agreement with Cara Care

Healthcare | TMT

Bayer AG has entered into a takeover agreement with Cara Care

Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.

Learn more

Duke Capital Limited has completed a fundraising

Financial Services

Duke Capital Limited has completed a fundraising

Duke Capital Limited has completed a successful fundraise, securing US$29.8 million (£23.5 million) through a placing and retail offer on the Alternative Investment Market (AIM). This milestone will further enable Duke Capital to continue its innovative approach to alternative financing solutions for small and medium enterprises (SMEs) across the UK and Europe.

Learn more